Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05482568
Other study ID # SHR-A1811-II-203
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 15, 2022
Est. completion date December 30, 2024

Study information

Verified date October 2023
Source Jiangsu HengRui Medicine Co., Ltd.
Contact Suqiang Yu
Phone +0518-82342973
Email suqiang.yu@hengrui.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.


Recruitment information / eligibility

Status Recruiting
Enrollment 324
Est. completion date December 30, 2024
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements 2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation 3. The ECOG score is 0 or 1 4. The expected survival is =12 weeks 5. Subjects with advanced or metastatic non-small cell lung cancer 6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided 7. Subjects who have failed prior standard care or are intolerant to standard care 8. There is at least one measurable lesion 9. Vital organs are functioning well 10. Heart function is good 11. Agree to birth control Exclusion Criteria: 1. There are untreated or active central nervous system (CNS) tumor metastases 2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration 3. Systemic antitumor therapy was performed 4 weeks prior to study initiation 4. Prior treatment with antibody-conjugated drugs 5. Received >30 Gy chest radiation within 6 months prior to initial administration 6. Palliative radiotherapy was completed within 7 days prior to initial administration 7. Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE =1 8. The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected 9. Received systemic immunosuppressant therapy within 14 days prior to the first study 10. Subjects with known or suspected interstitial pneumonia 11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration 12. Presence of any active, known or suspected autoimmune disease 13. Have poorly controlled or severe cardiovascular disease 14. Previous or concurrent malignancy 15. Subjects who developed a severe infection within 28 days prior to the first dose 16. Active hepatitis B 17. There were active tuberculosis patients within 1 year before enrollment 18. There is a history of immunodeficiency 19. Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment 20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter 21. Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration 22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316 23. History of severe allergic reactions to other monoclonal antibody/fusion protein drugs 24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study 25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention 26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Drug: SHR-A1811 & Pyrotinib SHR-A1811: intravenous Pyrotinib:oral Drug: SHR-A1811 & SHR-1316 SHR-A1811: intravenous SHR-1316: intravenous

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Shanghai Chest hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT(Phase I (dose exploration phase) main study endpoint) 21 days after the first administration of each subject
Primary AE(Phase I (dose exploration phase) main study endpoint) Two years after the last subject was enrolled in the group
Primary Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) main study endpoint) Two years after the last subject was enrolled in the group
Primary Objective response rate(The main end points of the second stage (efficacy expansion stage)) Two years after the last subject was enrolled in the group
Secondary Toxin binding antibody to shr-a1811(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Total antibody to shr-a1811(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of free toxin shr169265(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of pyrroltinib(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of SHR-1316(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Anti shr-a1811 antibody positive(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary The positive status of neutralizing antibody against shr-a1811(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Anti shr-1316 antibody positive(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary The positive status of neutralizing antibody against shr-1316(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Objective Response Rate(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Duration of response(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary Progression Free Survival(Phase I secondary endpoint) Two years after the last subject was enrolled in the group
Secondary AE(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Incidence and severity of serious adverse events (SAE)(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Toxin binding antibody to shr-a1811(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Total antibody to shr-a1811(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of free toxin shr169265(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of pyrroltinib(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Plasma concentration of SHR-1316(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Anti shr-a1811 antibody positive(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary The positive status of neutralizing antibody against shr-a1811(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Anti shr-1316 antibody positive(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary The positive status of neutralizing antibody against shr-1316(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Duration of response(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
Secondary Progression Free Survival(Phase II secondary study endpoint) Two years after the last subject was enrolled in the group
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04263051 - Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer Phase 2
Recruiting NCT05489731 - VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer Phase 1
Completed NCT01240447 - Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients Phase 2
Completed NCT00737867 - Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer Phase 3
Recruiting NCT05504278 - Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation Phase 1
Recruiting NCT06043973 - Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance Phase 3
Completed NCT00948675 - Study of Participants With Advanced Non-Small Cell Lung Cancer Phase 3
Active, not recruiting NCT03681483 - RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Phase 1
Terminated NCT05001724 - KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent Phase 2/Phase 3
Recruiting NCT05099172 - First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Phase 1/Phase 2
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00874328 - A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Completed NCT00487669 - Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT03516981 - A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Phase 2
Recruiting NCT03334864 - Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
Terminated NCT00783471 - Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00330746 - CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer Phase 2
Completed NCT03117335 - Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer Phase 3
Terminated NCT00345059 - The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer Phase 3
Completed NCT01980212 - Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer